Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Dosing of Romiplostim in ITP
NCT00116688Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2004
- Primary completion
- Jan 2010
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of romiplostim in immune thrombocytopenic purpura (ITP), sponsored by Amgen. Primary endpoint: Number of Participants With Adverse Events up to 285 weeks. Started Aug 2004; status: completed.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT00116688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116688.